MedPath

Insulin Lispro

Generic Name
Insulin Lispro
Brand Names
Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
Drug Type
Biotech
CAS Number
133107-64-9
Unique Ingredient Identifier
GFX7QIS1II
Background

Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.

Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin lispro, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually cause cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as Metformin, Gliclazide, or Sitagliptin have been tried, and when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.

Marketed as the brand name product Humalog, insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as Insulin detemir, Insulin degludec, or Insulin glargine to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.

Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli and was the first commercially available insulin analog. Formerly called LYSPRO from the chemical nomenclature LYS(B28), PRO(B29), insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared to endogenous human insulin.

Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.

Indication

本品尤其适用于下列情况:

1.经常发生低血糖的1型糖尿病者,使用本品可减少低血糖的发生率;

2.生活不规律,外出活动较多的用胰岛素治疗的糖尿病患者,本品快速、短效的特点有助于及时调整胰岛素的用量。

Associated Conditions
Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)

Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial

Phase 3
Active, not recruiting
Conditions
Dry Eye
Sjogren Syndrome
Interventions
Other: Autologous serum
First Posted Date
2025-04-16
Last Posted Date
2025-04-16
Lead Sponsor
Instituto de Oftalmología Fundación Conde de Valenciana
Target Recruit Count
25
Registration Number
NCT06931041
Locations
🇲🇽

Instituto de Oftalmologia Conde de Valenciana IAP, Mexico City, Mexico

Perioperative Glucose Monitoring and Treatment to Reduce Risk of Surgical Site Infections and Complications

Not Applicable
Conditions
Surgical Site Infections
Stress Hyperglycemia
Interventions
Diagnostic Test: glucose testing
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
St. Peter's Hospital, Albany, NY
Target Recruit Count
266
Registration Number
NCT06765655
Locations
🇺🇸

St. Peter's Hospital, Albany, New York, United States

A Trial of Three- and Seven-days Insulin Infusions Set

Not Applicable
Recruiting
Conditions
Type 1 Diabetes
Interventions
Device: Mio Advanced infusions set
Device: Extended wear insulin infusion (EWIS)
First Posted Date
2024-08-01
Last Posted Date
2024-08-06
Lead Sponsor
Steno Diabetes Center Copenhagen
Target Recruit Count
80
Registration Number
NCT06532461
Locations
🇩🇰

Steno Diabetes Center Copenhagen, Herlev, Capital, Denmark

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Phase 4
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2024-04-17
Last Posted Date
2025-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
112
Registration Number
NCT06370715
Locations
🇮🇳

Osmania Medical College & Hospital, Hyderabad, Andhra Pradesh, India

🇮🇳

King George Hospital, Visakhapatnam, Visakhapatnam, Andhra Pradesh, India

🇮🇳

Diabetes Research Centre, Royapuram, Chennai India, India

and more 9 locations

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

Phase 1
Recruiting
Conditions
Healthy
Type 1 Diabetes Mellitus
Interventions
First Posted Date
2024-02-28
Last Posted Date
2025-05-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
70
Registration Number
NCT06280703
Locations
🇩🇪

Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany

A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: THDB0206 injection
Drug: BC222insulin lispro injection
First Posted Date
2023-12-01
Last Posted Date
2023-12-01
Lead Sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Target Recruit Count
39
Registration Number
NCT06153329
Locations
🇨🇳

West China Hospital of Sichuan University, Sichuan, China

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

Phase 2
Recruiting
Conditions
type1diabetes
Diabetes Mellitus, Type 1
Interventions
Device: Automated Insulin Delivery (AID) system
First Posted Date
2023-09-21
Last Posted Date
2024-04-18
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
30
Registration Number
NCT06046417
Locations
🇨🇦

Research Institute of the McGill University Health Center, Montreal, Quebec, Canada

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

Not Applicable
Completed
Conditions
Type 1 Diabetes
Type 2 Diabetes
Type 2 Diabetes Treated With Insulin
Interventions
Device: Tempo Smart Button
Device: Dexcom G6 CGM
Device: Glooko Research Medical App (RMA)
First Posted Date
2023-06-08
Last Posted Date
2024-11-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
36
Registration Number
NCT05893797
Locations
🇫🇷

Centre Hospitalier Sud Francilien-Pharmacie, Corbeil-Essonnes, France

🇫🇷

CHU de Caen Hôpital Cote de Nacre, Caen, Cedex 9, France

🇫🇷

Chu de Grenoble, Grenoble Cédex 9, France

and more 6 locations

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

Phase 3
Recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: THDB0206 Injection
First Posted Date
2023-04-28
Last Posted Date
2023-04-28
Lead Sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Target Recruit Count
805
Registration Number
NCT05834868
Locations
🇨🇳

Zhongshan Hospital, Shanghai, China

Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents

Not Applicable
Active, not recruiting
Conditions
Depression
Major Depressive Disorder
Interventions
Drug: Saline nasal spray
First Posted Date
2022-10-07
Last Posted Date
2025-02-24
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
24
Registration Number
NCT05571878
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath